ArticleBreast care (Basel, Switzerland)2020
International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts.
Article in Breast care (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- An Overview of the Safety Profile and Clinical Impact of CDK4/6 Inhibitors in Breast Cancer-A Systematic Review of Randomized Phase II and III Clinical Trials.Biomolecules · 2023Pooled it
- Prior Clinico-Radiological Features Informed Multi-Modal MR Images Convolution Neural Network: A novel deep learning framework for prediction of lymphovascular invasion in breast cancer.Cancer medicine · 2024Trial
- Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046.Journal of cancer research and clinical oncology · 2021Trial
- Tumor characteristics and survival rate of axillary metastatic breast cancer patients: a three decades retrospective cohort study.Scientific reports · 2025Article
- Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study.BMC cancer · 2025Observational
- Real-World Experience of Metronomic Chemotherapy in Metastatic Breast Cancer: Results of a Retrospective Unicenter Study.Breast care (Basel, Switzerland) · 2023Article
- Review
- Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy.Breast care (Basel, Switzerland) · 2022Article
- Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases.Current oncology reports · 2022Review
- Awareness and Availability of Routine GermlineBreast care (Basel, Switzerland) · 2022Article
- Article
- First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center.Breast care (Basel, Switzerland) · 2021Article
- Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe.Breast (Edinburgh, Scotland) · 2021Review
- Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.Breast cancer : basic and clinical research · 2021Review
- Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.Therapeutic advances in medical oncology · 2021Article
- Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.Breast cancer research and treatment · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 5th International Consensus Conference for Advanced Breast Cancer (ABC5) took place on November 14-16, 2019, in Lisbon, Portugal. Its aim is to standardize the treatment of advanced breast cancer based on the available evidence and to ensure that all breast cancer patients worldwide receive adequate treatment and access to new therapies. This year, the conference focused on developments and study results in the treatment of patients with hormone receptor-positive/HER2-negative breast cancer as well as precision medicine. As in previous years, patient advocates from around the world were integrated into the ABC conference and had seats on the ABC consensus panel. In the present paper, a working group of German breast cancer experts comments on the results of the on-site ABC5 consensus votes by ABC panelists regarding their applicability for routine treatment in Germany. These comments take the recommendations of the Breast Committee of the Gynecological Oncology Working Group (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.